Oxidative stress and inflammation in COVID-19 pathogenesis

Кукес, В. Г.; Parfenova, O K; Сидоров, Александр Викторович; Olefir, Yuri V.; Gazdanova, A.A.

doi:10.17816/0869-2106-2020-26-4-244-247

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Этоксидол ускоряет диссоциацию оксигемоглобина на гемоглобин и кислород в эритроцитах, усиливает насыщение крови кислородом, тем самым улучшая оксигенацию. При этом Этоксидол дополнительно увеличивает концентрацию фоллистатина, способствуя ограничению воспалительного процесса в легких, снижая содержание провоспалительных цитокинов, концентрацию и активность активина А путем его связывания с фоллистатином, а также нейтрализуя активные формы кислорода [21].…”

Section: терапия Long Covid-19unclassified

Combined Therapy of COVID-19 Infection Consequences

Воробьева¹,

Moscow²

2021

View full text Add to dashboard Cite

Objective of the Review: To present clinical characteristics, pathogenic mechanisms and therapies of Long COVID-19. Key Points. Long COVID-19 is a set of chronic symptoms, which can be recorded in patients after acute COVID-19. These conditions are characterised by various types and combinations of clinical symptoms during various periods of time. Usually, there are two groups of symptoms: pulmonary symptoms and a set of symptoms similar to chronic fatigue syndrome. Balanced combined therapies of Long COVID-19 are discussed. Conclusion. Complex symptoms of Long COVID-19 require specific therapy; primary medications should be selected depending on their effect on primary/target symptoms (pulmonary, intolerance to exertion, cognitive disorders, etc.). We present a rough algorithm of a combined Long COVID-19 therapy. Keywords: COVID-19 pandemic, Long COVID-19, post-COVID respiratory symptoms, chronic fatigue syndrome, therapy.

show abstract

Section: терапия Long Covid-19unclassified

Combined Therapy of COVID-19 Infection Consequences

Воробьева¹,

Moscow²

2021

View full text Add to dashboard Cite

show abstract

Hypertension and cognitive impairment: relationship and management approaches

2022

View full text Add to dashboard Cite

Hypertension (HTN) is currently regarded as the most prevalent risk factor, which can lead to both stroke and cognitive impairment. The versatility and similarity of HTN and chronic cerebral ischemia (CCI) pathogenetic mechanisms should be considered in prevention and treatment strategies. The severity of pathological changes in central nervous system (CNS) depends on the degree of HTN and concomitant neurological pathologies. The drug effects on both vascular and cognitive dysfunctions as well as comorbidities and polypharmacy should be considered. The use of agents with polymodal pleiotropic effects both at metabolic and circulation levels appears feasible and rewarding ethylmethylhydroxypyridine malate can be recommended in HTN co-existent with CCI and cognitive disorders. The combination therapy of ethylmethylhydroxypyridine malate with antihypertensive, anti-ischemic drugs, anticoagulants and statins has been proven to be safe, shows low risk of adverse events and can be implemented in a wide range of vascular and comorbid diseases.

show abstract

Possibilities of personalized pharmacotherapy and medical rehabilitation of patients with long COVID from the perspective of clinical metabolomics

et al. 2023

View full text Add to dashboard Cite

Introduction. The material presents the results of the study of the effectiveness of the drug Ethylmethylhydroxypyridine malate in patients with long COVID, based on the dynamics of clinical manifestations and metabolomic parameters responsible for the level of oxidative stress. Aim. Evaluation of efficacy and registration of adverse reactions of ethylmethylhydroxypyridine malate administration to decrease oxidative stress level and reduce symptoms of asthenia and cognitive disorders in patients with long COVID. Materials and methods. 24 patients diagnosed with U09.9 “Condition after COVID-19 unspecified” were included in a non-randomized controlled prospective study, Patients were divided into 2 groups of 12 each. The experimental group received Ethylmethylhydroxypyridine malate tablets chewable 100 mg in a dosage of 400 mg/day. Clinical assessment by scales (mMRC dyspnea scale; 6-minute walk test (6MWT); MFI-20 subjective asthenia assessment scale; Montreal Cognitive Assessment Scale (MoCA); Barthel Baseline Functional Activity Rating Scale), and determination of metabolomic parameters were performed on days 1 and 14–18 of the study. Results. Use of the drug ethylmethylhydroxypyridine malate in patients with long COVID, led to a decrease in the level of oxidative stress, and normalization of mitochondrial function, as well as more pronounced improvements of the clinical picture. According to the scale of evaluation of asthenia (MFI-20) in the group of patients who received ethylmethylhydroxypyridine malate improvement of 21% was noted, in the control group improvement of 13% was noted. According to cognitive impairment assessment scale (MoCA), the drug group showed 20% improvement, while the control group showed 12,5% improvement. Conclusion. The drug ethylmethylhydroxypyridine malate tablets chewable 100 mg in a dosage of 400 mg/day demonstrates clinical efficacy characterized by, among other things, a decrease in oxidative stress, as well as clinical safety due to the absence of development of adverse reactions in patients with long COVID.

show abstract

Oxidative stress and inflammation in COVID-19 pathogenesis

Cited by 3 publications

References 10 publications

Combined Therapy of COVID-19 Infection Consequences

Combined Therapy of COVID-19 Infection Consequences

Hypertension and cognitive impairment: relationship and management approaches

Possibilities of personalized pharmacotherapy and medical rehabilitation of patients with long COVID from the perspective of clinical metabolomics

Contact Info

Product

Resources

About